Last updated on April 24, 2014 at 17:35 EDT

Oramed Pharmaceuticals Files US Patent Application for Combination Oral Treatment of Diabetes

January 10, 2012

JERUSALEM, January 10, 2012 /PRNewswire/ –

Oramed Pharmaceuticals Inc. (OTCBB:ORMP) (http://www.oramed.com
[http://us.lrd.yahoo.com/SIG=11adsmcif/EXP=1326899031/**http%3A/www.oramed.com ]), a
developer of oral drug delivery systems, announced today that it has filed a provisional
patent application with the United States Patent and Trademark Office for a combination
therapy of its lead compound, ORMD-0801 in combination with its oral exenatide
formulation, ORMD-0901. There is no such approved combination product available on the
market today.

The complexity of the development and progression of diabetes often requires
concomitant treatments, designed to simultaneously target the numerous underlying
pathological triggers. The combined use of these two drugs has recently been evaluated in
animals and showed improved blood glucose regulation when compared to the administration
of each drug separately.

These formulations have been designed to allow for oral delivery of drugs currently
only available in injectable forms. Both drugs are currently being independently assessed
in human clinical trials. An oral delivery system may substantially increase patient
compliance, especially at the earliest of stages of treatment, which would have a
meaningful outcome on quality of life and workplace productivity.

According to a report by Medtech Insight, diabetes affects nearly 24 million people in
the U.S. and an estimated 246 million adults worldwide. Being one of the most expensive
diseases, it costs the US healthcare system more than $130 billion per year and the market
for direct pharmaceutical care is close to $15 billion.

“This intriguing development is part of the company’s strategy to further expand our
pipeline in a very focused manner. Expansion of Oramed Pharmaceuticals’ intellectual
property portfolio and related programs will further enhance our ability to offer a higher
return on investment to our shareholders as we continue pioneering advances in drug
delivery options,” stated Oramed Pharmaceuticals’ CEO, Mr. Nadav Kidron.

Each of the formulations alone is currently patent pending in the US and other key
markets around the world. ORMD-0801 is an orally ingestible insulin capsule and has
recently demonstrated a favorable effect when evaluated in Phase II clinical trials for
its effectiveness in treating Type II diabetes. ORMD-0901 is a glucagon-like peptide-1
analog, a gastrointestinal hormone that stimulates the secretion of insulin from the
pancreas. Oramed commenced human clinical trials for ORMD-0901 following successful
pre-clinical results.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking to
revolutionize the treatment of diabetes through its patented flagship product, an orally
ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006,
Oramed’s technology is based on over 25 years of research by top research scientists at
Jerusalem’s Hadassah Medical Center. The Company’s corporate and R&D headquarters are
based in Jerusalem. For more information, please visit http://www.oramed.com
[http://us.lrd.yahoo.com/SIG=11adsmcif/EXP=1326899031/**http%3A/www.oramed.com ]

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements expressed or
implied by such forward looking statements, including the risks and uncertainties related
to the progress, timing, cost, and results of clinical trials and product development
programs; difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies; and the
company’s ability to obtain additional funding required to conduct its research,
development and commercialization activities. Please refer to the company’s filings with
the Securities and Exchange Commission for a comprehensive list of risk factors that could
cause actual results, performance or achievements of the company to differ materially from
those expressed or implied in such forward looking statements. The company undertakes no
obligation to update or revise any forward-looking statements.

        Company Contact:
        Oramed Pharmaceuticals
        Tara Horn
        Cell: +972-54-334-318
        Office: +972-2-566-0001
        Email: tara@oramed.com

SOURCE Oramed Pharmaceuticals Inc.

Source: PR Newswire